Management of Symptomatic Refractory Hypoglycemia at the End of Life in a Nondiabetic Patient With Metastatic Urothelial Carcinoma.
Christine M BuiSamantha SovichMichael A SpikerPublished in: Journal of palliative medicine (2023)
Patients with advanced cancer can develop symptomatic hypoglycemia at the end of life which can be associated with significant distress. We report the case of a man with metastatic urothelial carcinoma who developed acute-onset, recurrent, and symptomatic hypoglycemia concerning for non-islet cell tumor hypoglycemia (NICTH). Hypoglycemic episodes were physically and emotionally distressing and refractory to glucose tablets and a low concentration of dextrose infusion. Based on symptom burden and goals of care, treatment was escalated to a concentrated dextrose infusion requiring a central venous line, oral corticosteroids, and subcutaneous somatotropin. He was transferred to the inpatient palliative service, and on this treatment regimen, did not have additional distressing hypoglycemia. For patients with metastatic cancer and symptomatic hypoglycemia, applying a palliative-based framework with discussion of prognosis, values, and goals will lead to goal-concordant care at the end of life that can include aggressive maintenance of euglycemia to relieve suffering.
Keyphrases
- palliative care
- advanced cancer
- type diabetes
- glycemic control
- healthcare
- squamous cell carcinoma
- small cell lung cancer
- mental health
- low dose
- blood glucose
- stem cells
- liver failure
- pain management
- insulin resistance
- combination therapy
- drug induced
- mesenchymal stem cells
- bone marrow
- adipose tissue
- skeletal muscle
- case report
- intensive care unit
- squamous cell
- replacement therapy